Loading...
XNASBVS
Market cap579mUSD
Jan 14, Last price  
8.87USD
1D
-3.17%
1Q
-31.35%
IPO
-48.49%
Name

Bioventus Inc

Chart & Performance

D1W1MN
XNAS:BVS chart
P/E
P/S
1.13
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
2.41%
Rev. gr., 5y
9.93%
Revenues
512m
+0.04%
64,774,000232,375,000242,893,000253,650,000274,500,000292,059,000319,177,000340,141,000321,161,000430,898,000512,117,000512,345,000
Net income
-156m
L-26.79%
-39,222,000-22,367,000-12,900,000-34,111,000-17,953,000-1,639,000-12,207,0006,851,00016,411,0009,586,000-213,391,000-156,230,000
CFO
15m
P
2,749,00015,109,00018,920,00045,187,00040,713,00071,799,00022,991,000-13,537,00015,344,000
Earnings
Mar 10, 2025

Profile

Bioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions comprise bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company's restorative therapies include an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.
IPO date
Feb 11, 2021
Employees
950
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
512,345
0.04%
512,117
18.85%
Cost of revenue
501,477
539,584
Unusual Expense (Income)
NOPBT
10,868
(27,467)
NOPBT Margin
2.12%
Operating Taxes
85
(50,508)
Tax Rate
0.78%
NOPAT
10,783
23,041
Net income
(156,230)
-26.79%
(213,391)
-2,326.07%
Dividends
Dividend yield
Proceeds from repurchase of equity
778
2,470
BB yield
-0.24%
-1.54%
Debt
Debt current
27,848
33,056
Long-term debt
377,571
399,807
Deferred revenue
Other long-term liabilities
46,084
189,289
Net debt
368,455
398,413
Cash flow
Cash from operating activities
15,344
(13,537)
CAPEX
(7,362)
(11,520)
Cash from investing activities
15,807
(116,436)
Cash from financing activities
(26,653)
62,076
FCF
(82,355)
69,326
Balance
Cash
36,964
31,814
Long term investments
2,636
Excess cash
11,347
8,844
Stockholders' equity
(273,136)
(141,587)
Invested Capital
935,184
1,086,702
ROIC
1.07%
2.36%
ROCE
1.64%
EV
Common stock shares outstanding
62,648
61,389
Price
5.27
101.92%
2.61
-81.99%
Market cap
330,153
106.05%
160,226
-81.43%
EV
746,135
582,390
EBITDA
68,233
39,336
EV/EBITDA
10.94
14.81
Interest
40,676
25,795
Interest/NOPBT
374.27%